menu
    • menu
    [{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series A Financing","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Mytos","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ Mytos","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Mytos"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Aspen Neuroscience

    Menu

    Aspen Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Mytos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Mytos & Aspen Partner to Automate Parkinson’s Disease Cell Therapy Manufacturing

                            Details : The collaboration aims to advance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Mytos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : California Institute for Regenerative Medicine (CIRM)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2a Study of ANPD001 in Parkinson Disease

                            Details : ANPD001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 03, 2024

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : California Institute for Regenerative Medicine (CIRM)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cel...

                            Details : ANPD001 is an investigational cell therapy product being studied as an autologous neuron replacement for Parkinson’s disease. Aspen’s personalized 3-step manufacturing approach starts from a small sample of the patient’s own skin cells.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 08, 2023

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Aspen Neuroscience

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : OrbiMed Advisors

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Aspen Neuroscience Announces $70 Million Series A Financing to Advance First Autologous Neuron Replacement The...

                            Details : The funding will support the completion of all remaining IND-enabling studies and FDA submission of the IND relating to Aspen's lead product (ANPD001).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 01, 2020

                            Lead Product(s) : ANPD001

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : OrbiMed Advisors

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth